Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 368

Sort by

Sort Order Select

Journal Articles

Predicting the future: adult T-cell leukemia

Lee Ratner

Blood (2020) 135 (23): 2013–2014.

https://doi.org/10.1182/blood.2020005552

Published: 2020

Journal Articles

Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia/lymphoma diagnosis

Aileen G. Rowan, Richard Dillon, Aviva Witkover, Anat Melamed, Maria-Antonietta Demontis, Nicolas A. Gillet, Liew Jun Mun, Charles R. M. Bangham, Lucy B. Cook, Paul A. Fields, Graham P. Taylor

Blood (2020) 135 (23): 2023–2032.

https://doi.org/10.1182/blood.2019002665

Published: 2020

Includes: Supplemental data

Journal Articles

Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions

Noriaki Yoshida, Kay Shigemori, Nicholas Donaldson, Christopher Trevisani, Nicolas A. Cordero, Kristen E. Stevenson, Xia Bu, Fumiko Arakawa, Mai Takeuchi, Koichi Ohshima, Akinori Yoda, Samuel Y. Ng, David M. Weinstock

Blood (2020) 135 (17): 1467–1471.

https://doi.org/10.1182/blood.2019001815

Published: 2020

Includes: Supplemental data

Journal Articles

Feed-forward regulatory loop driven by IRF4 and NF-κB in adult T-cell leukemia/lymphoma

Regina Wan Ju Wong, Tze King Tan, Stella Amanda, Phuong Cao Thi Ngoc, Wei Zhong Leong, Shi Hao Tan, Kaori Asamitsu, Yurina Hibi, Ryuzo Ueda, Takashi Okamoto, Takashi Ishida, Shinsuke Iida, Takaomi Sanda

Blood (2020) 135 (12): 934–947.

https://doi.org/10.1182/blood.2019002639

Published: 2020

Includes: Supplemental data

Journal Articles

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Steven M. Horwitz, MD, Tatyana A. Feldman, MD, Brian T. Hess, MD, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Javier Munoz, MD MS, FACP, Manish R. Patel, MD, Tycel J. Phillips, MD, Stephen D. Smith, MD, Sonali M. Smith, MD, Ryan A. Wilcox, MD PhD, Matt R. Birrell, Janet M. Leeds, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, Gregory P. Coffey, PhD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 466.

https://doi.org/10.1182/blood-2019-123986

Published: 2019

Journal Articles

VAV1 Mutations Contributes to the Development of T-Cell Malignancies in Mice

Kota Fukumoto, MD, Mamiko Sakata-Yanagimoto, MD PhD, Manabu Fujisawa, MD, Tatsuhiro Sakamoto, MD PhD, Tran B. Nguyen, Sakurako Suma, MD, Hiroaki Miyoshi, MD PhD, Koichi Ohshima, MD PhD, Keisuke Kataoka, MD PhD, Seishi Ogawa, MD PhD, Shigeru Chiba, MD PhD

Blood (2019) 134 (Supplement_1): 300.

https://doi.org/10.1182/blood-2019-124591

Published: 2019

Journal Articles

Understanding the Mechanisms Driving Genomic Instability in Adult T-Cell Leukemia/Lymphoma

Advaitha Madireddy, PhD, Angelica Barreto-Galvez, B. Hilda Ye, PhD

Blood (2019) 134 (Supplement_1): 5042.

https://doi.org/10.1182/blood-2019-121565

Published: 2019

Journal Articles

Toxicity of a Modified Peg-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population

Ryan J Caddell, PharmD, BCOP, Hayder Saeed, MD, Rebecca Nelson, PharmD, BCOP, Leidy Isenalumhe, MD, Julio Chavez, Celeste Bello, MD, Javier Pinilla Ibarz, MD PhD, Lubomir Sokol, MD PhD, Bijal Shah, MD

Blood (2019) 134 (Supplement_1): 5292.

https://doi.org/10.1182/blood-2019-128435

Published: 2019

Journal Articles

Results from Treatment of a Large Cohort of ATL Patients from a Country with High HTLV1 Prevalence

Blood (2019) 134 (Supplement_1): 5288.

https://doi.org/10.1182/blood-2019-126434

Published: 2019

Journal Articles

Identifying a Simple Clinical Prognostic Model for Aggressive Adult T-Cell Leukemia/Lymphoma in Latin American Population and Its Validation: A Large International Study of the Latin America Working Group for Lymphomas (GELL)

Luis E Malpica Castillo, MD, Camila Peña, MD, Christine Rojas, MD, Pilar León, MD, Brady E. Beltrán, MD, Denisse A. Castro, MD, Yesenia M. Huerta- Collado, MD, Mimsy Quinones, MD, Sally Rose Paredes, MD, Henry Idrobo, MD, Ivan Perdomo, MD, Virginia Abello, MD, Lorena Fiad, MD, Victoria Otero, MD, Marialejandra Torres Viera, MD, Luis Villela M, Eduardo Sotomayor, MD, Jorge J Castillo, MD, Juan Carlos Ramos, MD BS

Blood (2019) 134 (Supplement_1): 4045.

https://doi.org/10.1182/blood-2019-122976

Published: 2019

Journal Articles

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

Alex F. Herrera, MD, Jasmine Zain, MD, Kerry J Savage, BSc, MD MSc, Tatyana A. Feldman, MD, Jonathan E Brammer, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Lacolle Peters, Yaira Kurtzman, Stephen J Forman, MD, Steven Rosen, MD, Larry W Kwak, MD PhD, Swaminathan P. Iyer, MD

Blood (2019) 134 (Supplement_1): 4023.

https://doi.org/10.1182/blood-2019-123166

Published: 2019

Journal Articles

Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas

Stefan K. Barta, MD MRCP, MS, Nathan H. Fowler, MD, Jasmine Zain, MD, Jia Ruan, MD PhD, Sonali M. Smith, MD, Stephen J. Schuster, MD, Sunita D Nasta, MD, Jakub Svoboda, MD, James N Gerson, MD, Daniel J. Landsburg, MD, Elise A. Chong, MD, Henry C. Fung, FRCP,MBBChir, Kerry S Campbell, PhD, Nadia Khan, MD, Richard I. Fisher, MD, Carlyn Rose Tan, MD

Blood (2019) 134 (Supplement_1): 4031.

https://doi.org/10.1182/blood-2019-125385

Published: 2019

Journal Articles

Improved Overall Survival Among Newly Diagnosed Aggressive Adult T-Cell Leukemia/Lymphoma Patients Treated with Mogamulizumab Plus EPOCH Compared to Mogamulizumab Plus Vcap-AMP-Vecp

Tatsuro Jo, MD PhD, Kaori Matsuzaka, Haruna Shioya, Hiroo Tominaga, Takahiro Sakai, Yohei Kaneko, Shizuka Hayashi, Masatoshi Matsuo, MD, PhD, Jun Taguchi, MD PhD, Kazuto Shigematsu, MD PhD

Blood (2019) 134 (Supplement_1): 4048.

https://doi.org/10.1182/blood-2019-123984

Published: 2019

Journal Articles

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma

Mehrdad Mobasher, MD MPH, Richard A. Miller, MD, James W. Janc, PhD, Long Kwei, PhD, Joseph J. Buggy, PhD, Gabriel Luciano, Anahita Mohammady, PharmD, Won Seog Kim, MD PhD, Youn H. Kim, MD, Michael S. Khodadoust, MD PhD, Steven M. Horwitz, MD, Dejan Radeski, MBBS, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 4030.

https://doi.org/10.1182/blood-2019-124958

Published: 2019

Journal Articles

Baseline Total Lesion Glycolysis Combined with Interim PET/CT Is a Robust Predictor of Outcome in Patients with Peripheral T-Cell Lymphoma

Akihiro Kitadate, MD PhD, Kentaro Narita, MD, Kota Fukumoto, MD, Toshiki Terao, MD, Takafumi Tsushima, MD, Hiroki Kobayashi, MD, Yoshiaki Abe, MD, Daisuke Miura, MD, Masami Takeuchi, MD, Youichi Machida, MD, Naoto Takahashi, MD PhD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 2839.

https://doi.org/10.1182/blood-2019-122799

Published: 2019

Journal Articles

Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience

Zachary D. Epstein-Peterson, MD, Paola Ghione, MD, Alison J. Moskowitz, MD, Parastoo B. Dahi, MD, Ahmet Dogan, MD PhD, Anita Kumar, MD, Matthew J Matasar, MD, Ariela Noy, MD, Miguel-Angel Perales, MD, Doris M Ponce, MD, David J. Straus, MD, Andrew D. Zelenetz, MD PhD, Craig S. Sauter, MD, Steven M. Horwitz, MD

Blood (2019) 134 (Supplement_1): 2850.

https://doi.org/10.1182/blood-2019-125376

Published: 2019

Journal Articles

Aberrant SYK Expression As a Potential Therapeutic Target in T/NK Cell Neoplasms

Jing-Ping Zhang, PhD, Qi Gao, MLS, Alexander Chan, MD, Wenbin Xiao, MD PhD, Sary El Daker, PhD, Mikhail Roshal, MD PhD, Ahmet Dogan, MD PhD

Blood (2019) 134 (Supplement_1): 3978.

https://doi.org/10.1182/blood-2019-130406

Published: 2019

Journal Articles

Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma

Takashi Ishio, Joji Shimono, Sarvesh Kumar, Yuquan Lin, Emmanuel Bachy, Michael N. Petrus, Yandan Yang, Michiyuki Maeda, Hideki Goto, Satoshi Hashino, Takanori Teshima, MD, Thomas A. Waldmann, MD, Louis Staudt, MD, Masao Nakagawa

Blood (2019) 134 (Supplement_1): 3781.

https://doi.org/10.1182/blood-2019-124670

Published: 2019

Journal Articles

S-Phase Progression of North American ATLL Cells Is Critically Regulated By the Proto-Oncogene BCL6 and Targetable By PARP Inhibition

B. Hilda Ye, PhD, Elaine Chung, PhD, Kith Pradhan, PhD, Ana Acuna-Villaorduna, MD, Yanhua Wang, MD PhD, Aditi Shastri, MD, Advaitha Madireddy, PhD, Amit Verma, MBBS, R.Alejandro Sica, MD, Murali Janakiram, MD MS

Blood (2019) 134 (Supplement_1): 3779.

https://doi.org/10.1182/blood-2019-131364

Published: 2019

Journal Articles

Genomic Landscape of Young ATLL Patients Identifies Frequent Targetable CD28 Fusions

Noriaki Yoshida, MD PhD, Kay Shigemori, Samuel Y. Ng, MD PhD, Ajit Nirmal, PhD, Nicolas Donaldson, Nicolas Cordero, Kristen E. Stevenson, MS, Xia Bu, Mai Takeuchi, MD PhD, Koichi Ohshima, MD PhD, Akinori Yoda, PhD, David M Weinstock

Blood (2019) 134 (Supplement_1): 2760.

https://doi.org/10.1182/blood-2019-122525

Published: 2019

NARROW

Predicting the future: adult T-cell leukemia

Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia/lymphoma diagnosis

Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions

Feed-forward regulatory loop driven by IRF4 and NF-κB in adult T-cell leukemia/lymphoma

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

VAV1 Mutations Contributes to the Development of T-Cell Malignancies in Mice

Understanding the Mechanisms Driving Genomic Instability in Adult T-Cell Leukemia/Lymphoma

Toxicity of a Modified Peg-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population

Results from Treatment of a Large Cohort of ATL Patients from a Country with High HTLV1 Prevalence

Identifying a Simple Clinical Prognostic Model for Aggressive Adult T-Cell Leukemia/Lymphoma in Latin American Population and Its Validation: A Large International Study of the Latin America Working Group for Lymphomas (GELL)

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas

Improved Overall Survival Among Newly Diagnosed Aggressive Adult T-Cell Leukemia/Lymphoma Patients Treated with Mogamulizumab Plus EPOCH Compared to Mogamulizumab Plus Vcap-AMP-Vecp

A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma

Baseline Total Lesion Glycolysis Combined with Interim PET/CT Is a Robust Predictor of Outcome in Patients with Peripheral T-Cell Lymphoma

Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience

Aberrant SYK Expression As a Potential Therapeutic Target in T/NK Cell Neoplasms

Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma

S-Phase Progression of North American ATLL Cells Is Critically Regulated By the Proto-Oncogene BCL6 and Targetable By PARP Inhibition

Genomic Landscape of Young ATLL Patients Identifies Frequent Targetable CD28 Fusions

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only